Closed Loop Oxygen Control in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Nasal High Flow in the Hospital

ID#: NCT07222410

Age: 22 years - 66+

Gender: All

Healthy Subjects: No

Study Phase: N/A

Recruitment Status: Recruiting

Start Date: January 07, 2026

End Date: November 01, 2027

Contact Information:
Jenny Han
64 9 574 0123
Summary: The trial aims to evaluate whether the Airvo 3 device in OptiO2 mode can maintain patients' SpO2 levels within the target range better than manual oxygen titration in hospitalized COPD patients with hypoxemia/respiratory distress.
Eligibility:

Inclusion Criteria:

- Has cognitive ability to provide informed consent

- Aged 22 years or older

- Hospitalized with hypoxemia/respiratory distress

- Diagnosis of COPD

- Candidate for/currently prescribed nasal high flow (flow rate of at least 25 L/min) with supplemental oxygen, as assessed by the investigator

- Expected duration of oxygen and nasal high flow therapy >24 hours (not necessarily continuous)

Exclusion Criteria:

- Receiving Non Invasive Ventilation (NIV) or indicated for NIV as per European Respiratory Society /American Thoracic Society guidelines

- Hemodynamic instability (systolic blood pressure <90mmHg or requirement for vasopressor or inotropic support)

- Patient receiving end of life care

- Nasal or facial conditions precluding use of nasal high flow

- Pregnancy or breastfeeding

- Cognitive impairment or impaired consciousness precluding informed consent

- Unsuitable for adhesive finger pulse oximetry, as assessed by the investigator

- Any other condition which, at the investigator's discretion, is believed to present a safety risk to the patient if included

- The presence of any active comorbidities that affect the patient's condition importantly in the next 30 days, as assessed by the investigator

- Has already participated in this clinical trial
Find a Clinical Trial Find Cancer Clinical Trials